NL-OMON51042已完成不适用
Accurate multiple sclerosis atrophy measurement system - AMS2
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •MS patient group:
- •1. Clincally definite relapsing-remitting, secondary progressive, primary
- •progressive MS, according to McDonald criteria (2017).
- •2. 18 to 70 years old.
- •3. Be able to undergo 6 MRI scans (scan and rescan on three different MR
- •scanners) in one day
- •4. Written informed consent
- •Healthy controls:
- •1. 18 to 70 years old.
- •2. Written informed consent
排除标准
- •1. Inability to undergo MRI, e.g. metal objects in or around the body,
- •claustrophobia or inability to lie still in the
- •2. Pregnant
- •3. Past or current clinically relevant non-MS neurological or psychiatric
- •disorder(s)
- •4. Past or current clinically relevant (auto)immune disorder(s)
- •5. Colleagues from the same department, people directly involved in the study
- •or people with relevant relations to the aforementioned people (e.g. partner,
- •parent, sibling or child etc.).
研究者
相似试验
已完成
不适用
Standardization of brain atrophy measurement in MS patients10012303Multiple SclerosisNL-OMON43474Vrije Universiteit Medisch Centrum35
已完成
不适用
Proxy measurements in Multiple Sclerosis10029317Multiple SclerosisNL-OMON31939Vrije Universiteit Medisch Centrum300
已完成
不适用
3 Meter Backwards Walk Test and Multiple SclerosisWalking, DifficultyMultiple SclerosisDistorted BalanceNCT04004026Sanko University40
已完成
不适用
Diagnostic criteria for Multiple Sclerosis: Impact of high field Magnetic Resonance Imagingmultiple sclerosisMS1000381610012303NL-OMON40083Vrije Universiteit Medisch Centrum30
进行中（未招募）
不适用
Characterisation of multiple sclerosis pathology by ultra small particles of iron oxide (USPIO)” in comparison with conventional and advanced MRI imaging techniques[Charakterisierung der Multiple Sklerose Pathologie durch ultra small particles of iron oxide (USPIO)” im Vergleich zu konventionellen und fortgeschrittenen MRT Techniken] - MS_USPIO_MPIPPatients with Multiple Sclerosis (MS, N=90) and patients with a clinically isolated syndrome (ref. to as CIS in literature, i. e. not a clinically definite MS but a syndrome that may occur as first sign of MS early in the course, N=15) are planned to be investigated in the proposed clinical trial.MedDRA version: 8.1Level: LLTClassification code 10028245Term: Multiple sclerosisEUCTR2006-001337-17-DEMax-Planck-Institute of Psychiatry